NEW YORK (GenomeWeb) – Cancer Genetics on Thursday filed a shelf registration to offer up to $100 million in securities.
In its registration statement filed with the US Securities and Exchange Commission, the firm said that it may from time to time offer common stock, preferred stock, warrants, and overallotment purchase rights and units totaling up to $100 million in aggregate.
Net proceeds are intended for working capital and other general corporate purposes.
Cancer Genetics recently reported a 15 percent rise in revenues for its first quarter. The company said that it had cash and cash equivalents of $9.7 million at the end of Q1.